4 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple MyelomaBlood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic diseaseRecruitingPhase 22026-10-01NCT07589634
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's DiseaseCrohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorderActive, not recruitingPhase 2 / Phase 32026-09-28NCT03466411
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's DiseaseCrohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorderActive, not recruitingPhase 32026-09-25NCT05197049
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemiaautoimmune hemolytic anemia, warm typeActive, not recruitingPhase 2 / Phase 32026-08-31NCT04119050